SNY Sanofi American Depositary Shares (Each representing one-half of one ordinary share) Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:56
May 08
May 08
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis, including a biologic-refractory trial no pharma giant has run, could drive over $5B in peak sales and make NKTR a glaring M&A candidate at current prices.
HIGH
19:05
Apr 29
Apr 29
Adam May replies to Benjo McKazuie by simply listing the tickers $AZN, $LLY, and $SNY without any directional opinion or market context.
LOW
14:25
Apr 23
Apr 23
Short Sanofi because its pipeline drug is ineffective and dermatologists will not prescribe it based on brand alone, limiting revenue potential. Timeframe: medium-term
MED
18:13
Mar 28
Mar 28
The tweet highlights alarming safety concerns regarding rapid cancer development linked to OX40-induced treatments.
HIGH
17:27
Mar 28
Mar 28
The tweet suggests potential clinical trial failures for Sanofi and Nektar Therapeutics, signaling a negative outlook for both companies.
HIGH
16:30
Mar 28
Mar 28
The author highlights safety concerns regarding Sanofi's amlitelimab and questions Nektar Therapeutics' valuation in light of these developments.
HIGH
17:45
Mar 06
Mar 06
Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million https://t.co/wXcW78Sj9j https://t.co/wXcW78Sj9j
06:05
Feb 20
Feb 20
A major sell-side bank is lowering its price target, indicating a revised, more bearish outlook on the stock's forward performance.
MED
About SNY Analyst Coverage
Buzzberg tracks SNY (Sanofi American Depositary Shares (Each representing one-half of one ordinary share)) across 3 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 8 total trade ideas tracked.